Jubilant Pharmova shares drop nearly 5% after net profit slumps 45% in December quarter

Shares of Jubilant Pharmova fell as much as 4.7% to hit an intraday low of ₹893.60 on the National Stock Exchange (NSE) on Monday, February 9. On the BSE, Jubilant Pharmova shares declined as much as 4.37% to touch an intraday low of ₹893 amid spike in trading activity.

The Noida-based drug maker's shares came under selling pressure after the company post market hours on Friday, February 6, reported that its consolidated net profit in December quarter fell 45% to ₹56 crore from ₹101 crore in the same period last year. The sharp decline in profit came on the back of surge in expenses as its total expenses rose 20% to ₹2,010 crore from ₹1,681 crore.

Jubilant Pharmova's revenue from operations in October-December period advanced 17% to ₹2,116 crore from ₹1,814 crore in the year-ago period.

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) also known as operating profit rose 1% to ₹283 crore and its EBITDA margin contracted by 200 basis points to 13.4%.

During the quarter company had an exceptional expense on account of temporary suspension of manufacturing operations for remediation of "OAI" (Official Action Indicated) observations at contract manufacturing facility located at Montreal, Canada aggregating to, ₹44 crore, the company said.

Shyam S Bhartia, Chairman Jubilant Pharmova and Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova said, “We are pleased to announce revenue of ₹2,123 crore for Q3’FY26, which reflects a solid growth of 17% on YoY basis. Revenue growth is particularly driven by incremental revenue generation from the new & third line in CDMO Sterile Injectable business. We expect this growth momentum to continue as we make progress in the last quarter of current financial year. EBITDA for the period grew by 5% YoY to ₹310 crore due to improved performance in CDMO Sterile Injectables and CRDMO business.”

Radiopharmaceuticals Q3’FY26 revenue grew by 12% to ₹298 crore and EBITDA for the quarter stood at ₹122 crore. The business continues to maintain a strong position in the high margin SPECT imaging product portfolio.

Jubilant Pharmova shares were witnessing higher than usual trading activity as trading volume spiked by 2.6 times to 3.78 lakh shares on the NSE compared with a an average trading volume of 1.46 lakh shares.

As many as 12,000 shares changed hands on the BSE compared with an average of 5,683 shares traded daily in the past two weeks.

As of 1:46 om, Jubilant Pharmova shares traded 1.88% lower at ₹920, underperforming the NIFTY500 index which was down 1.25%.